1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies

Miragen Therapeutics Inc (MGEN) Files 10-K for the Fiscal Year Ended on December 31, 2018

March 14, 2019 | About:

Miragen Therapeutics Inc (NASDAQ:MGEN) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Miragen Therapeutics Inc is a clinical-stage biopharmaceutical company which engaged in discovering and developing proprietary RNA (Ribonucleic acid)-targeted therapeutics. Miragen Therapeutics Inc has a market cap of $83.880 million; its shares were traded at around $2.72 with and P/S ratio of 8.08. Miragen Therapeutics Inc had annual average EBITDA growth of 4.00% over the past five years.

For the last quarter Miragen Therapeutics Inc reported a revenue of $0.94 million, compared with the revenue of $1.63 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $8.39 million, an increase of 109.5% from last year. For the last five years Miragen Therapeutics Inc had an average revenue growth rate of 10.1% a year.

The reported loss per diluted share was $1.1 for the year, compared with the loss per share of $52.5 in the previous year. The Miragen Therapeutics Inc had an operating margin of -394.51%, compared with the operating margin of -662.8% a year before. The 10-year historical median operating margin of Miragen Therapeutics Inc is -256.11%. The profitability rank of the company is 2 (out of 10).

At the end of the fiscal year, Miragen Therapeutics Inc has the cash and cash equivalents of $32.6 million, compared with $47.4 million in the previous year. The company had no long term debt, compared with $9.92 million in the previous year. Miragen Therapeutics Inc has a financial strength rank of 5 (out of 10).

At the current stock price of $2.72, Miragen Therapeutics Inc is traded at 253.2% premium to its historical median P/S valuation band of $0.77. The P/S ratio of the stock is 8.08, while the historical median P/S ratio is 2.29. The stock lost 61.42% during the past 12 months.

For the complete 20-year historical financial data of MGEN, click here.

Rating: 0.0/5 (0 votes)


Please leave your comment:

Performances of the stocks mentioned by insider

User Generated Screeners

pascal.van.garsseHigh FCF-M2
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat